Psychedelics Filament Health gets FDA approval for psilocybin studies on cancer-related anxiety and depression The clinical trials will examine the effects of the company's botanical psilocybin drug candidate PEX010 Rowan DunneAugust 10, 2023
Psychedelics Cybin reaches end of psilocybin analogue clinical trial for depression CYB003 is a molecule developed by the company with rapid onset and a short duration Rowan DunneAugust 3, 2023
Psychedelics Optimi Health files U.S. patent for psilocybin extraction process The psychedelic drug developer says the new method increases potency while maintaining the mushroom's botanical qualities Rowan DunneAugust 1, 2023
News Optimi Health disputes allegations of failing $1.2M supply agreement The company announced the supply agreement last May Natalia Buendia CalvilloJuly 28, 2023
Psychedelics Psilocybin-like drug may help people suffering from anorexia: COMPASS study The majority of participants reported significant improvements in their overall mental health Rowan DunneJuly 28, 2023
Psychedelics Filament Health to list on Nasdaq through new business arrangement The transaction is expected to close in Q4 this year Rowan DunneJuly 19, 2023
Psychedelics Majority of Americans support regulating psychedelics: UC Berkeley survey The survey results follow the city of Berkeley decriminalizing psychedelic plants and fungi on Tuesday Rowan DunneJuly 13, 2023
Psychedelics UC San Diego receives US$1.5M for cognitive research on DMT Fund supporting the institution's Psychedelics and Health Research Initiative was provided by philanthropist Eugene Jhong Rowan DunneJuly 11, 2023
Psychedelics Windsor police raid new mushroom dispensary, owners open up shop next day 'We have a big team behind us and we have a lot of people supporting us' said the store's co-owner on Thursday Rowan DunneJuly 7, 2023
Psychedelics NeoLumina Bioscience to develop Filament Health patented psilocybin as eating disorders treatment Filament will be licensing NeoLumina with its PEX010 drug and associated IP for commercial and clinical development Rowan DunneJuly 3, 2023